Illumina

Circulating Tumor Cells, ctDNA, and cfRNA sequencing methods for Liquid Biopsy

Find in this guide published, comprehensive workflows for thorough characterization of liquid biopsy samples using NGS and Microarrays. To learn how to perform circulating tumor cell (CTC) sequencing, circulating tumor DNA (ctDNA) methylation profiling, ctDNA sequencing and cell-free RNA (cfRNA) sequencing, DOWNLOAD the FREE eBook

As liquid biopsy technology improves, cancer research stands to benefit

Biomarkers found in blood and urine can potentially provide more information, more easily and frequently, than a tissue biopsy

Read Article
Article Cover

Advancements in Translational Biomarker Identification from Cell-Free RNA

Learn about best-practices for sequencing cfRNAs that can empower non-invasive interrogations of cancer and further facilitate our transition into the era of personalized medicine.

View Recording

Company Legal
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see www.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.